Bardet--Biedl syndrome (BBS) is a rare autosomal recessive disorder characterized by rod-cone dystrophy, postaxial polydactyly, central obesity, hypogonadism, renal abnormalities, and mental retardation. BBS is often complicated by strabismus/cataracts/astigmatism, diabetes mellitus, Hirschsprung disease, heart disease, and/or liver fibrosis. To date, 21 causative genes have been reported, comprising \~80% of BBS genetic abnormalities^[@CR1],[@CR2]^. The remaining 20% of genetic abnormalities among BBS patients are not yet known. In the present study, we performed whole-exome sequencing (WES) of a classical BBS patient.

The patient was diagnosed with BBS at 8 years of age, in accordance with criteria reported previously^[@CR3]^. Primary and secondary signs of BBS in this patient are listed in Table [1](#Tab1){ref-type="table"}. When the patient first visited Osaka University Hospital at 17 years of age, his best-corrected visual acuity (BCVA) was 0.07 in the right eye and 0.2 in the left eye. At 28 years of age, his BCVA was 0.01 in the right eye and 0.04 in the left eye; he exhibited bilateral diffuse retinal degeneration, including macular atrophy, attenuated retinal vessels, and optic nerve head pallor with little pigmentary dispersion. His parents were not consanguineous. His mother showed no sign of BBS or rod-cone dystrophy. His father did not have symptoms of BBS.Table 1Primary and secondary signs of BBS in this patientAge of onsetClinical informationInterventionPrimary signs Rod-cone dystrophy8 Years oldVisual acuities: 0.01 (right), 0.04 (left), (with mild myopia and astigmatism)No medicationFundus finding: binocular diffuse retinal degenerationVisual field: centipede constriction (binocular)Optical coherence tomography: binocular diffuse thinning of outer retinal layer ( + ), macular atrophy ( + ), macular edema ( − ), cystic changes ( − ), elipsoid zone ( − )Fundus autofluorescence: binocular mottled pattern ( + ), perifoveal ring ( − ) PolydactylyAt birthBoth feetPlastic surgery (19 months old) Obesity9 Years oldHeight: 164 cmWeight: 78.1 kgBody mass index (BMI): 29 kg/m^2^No medication HypogonadismTestosterone: 300--600 ng/dlNo medication Renal anomalies1 Week oldCystic kidneyCreatinine: 1.79 mg/dlBUN: 21 mg/dleGFR cre: 37.2 mL/min/1.73 m^2^No medication Mental retardationNo\--Secondary signs Hirschsprung disease3 Months old-Surgery (28 months old) Abnormal glucose tolerance9 Years oldHbA1c: 5.6%,75 g oral glucose tolerance test: 82 mg/dL at 0 h, 185 mg/dL at 2 hNo medication ExotropiaNA-Bilateral lateral rectus muscle recession (14 years old) Hypertension27 Years oldBlood pressure = 145/83 mm HgOral medicine (Azilsartan 20 mg and Amlodipine besilate 3.47 mg per day) CataractNABinocular anterior sub-capsular cataract- Heart diseasesNo\-- Liver fibrosisNo\--

All experimental procedures were approved by the Ethics Committee at Osaka University (No. 719--2, Osaka, Japan) and conducted in accordance with the Declaration of Helsinki. Written informed consent was obtained from the patient (at the time of the report, a 28-year-old male) and his 61-year-old mother. Both individuals underwent ophthalmologic examinations: BCVA in decimal units, slit-lamp biomicroscopy, fundoscopy, visual field testing with Goldmann perimetry, optical coherence tomography (SSOCT; DRI OCT1, Topcon Corp., Tokyo, Japan), and fundus autofluorescence (Optos, Optos KK, Tokyo, Japan). Genomic DNA was extracted from blood samples using NucleoSpin Blood XL (Macherey-nagel, Düren, Germany). DNA libraries were constructed using SureSelectXT Human All Exon Kit V6 and SureSelectXT Reagent Kit (Agilent, Santa Clara, CA, USA) and then subjected to 100 bp paired-end sequencing on an Illumina HiSeq2500 Platform (Illumina, San Diego, CA, USA). Sequence reads were aligned to the reference human genome (UCSC hg19) in BWA (<http://www.bio-bwa.sourceforge.net/>) to align short reads after adaptor sequences were removed by Cutadapt (<https://cutadapt.readthedocs.io/en/stable/>). SAM tools (Version 0.1.17; <http://www.samtools.sourceforge.net/>) were used for sequence data conversion, sorting, and indexing. To exclude duplicate reads, Picard (<http://picard.sourceforge.net>) was used. Variants were determined using GATK (<http://www.broadinstitute.org/gatk/>). ANNOVAR (<http://www.openbioinformatics.org/annovar/>) was used to annotate the resulting genetic variants. Rare variants (minor allele frequency \< 0.05) were selected using the Exome Sequencing Project, 1000 Genomes Project, and Human Genetic Variation databases; possible pathogenic variants, such as nonsynonymous, nonsense, and frameshift mutations, were extracted from among the retinal degenerative disease-related genes registered in the Ret.Net.^TM^ database.

Ten candidate pathogenic rare variants in genes related to retinal degenerative diseases were detected in this patient. All were heterozygous variants; however, two novel nonsense (NM_001288781.1 \[TTC8_v001\]: c.226 C \> T, p.Q76X) and frameshift (NM_001288781.1 \[TTC8_v001\]: c.309_310insTA, p.T103fs) mutations were located in the *TTC8* gene (also known as *BBS8*). Both mutations were validated by direct sequencing of PCR products (Applied Biosystems 3730 DNA Analyzer; Thermo Fisher Scientific K.K., Tokyo, Japan). The primer sets used for PCR were as follows: c.226 C \> T, 5′-TGGGTTTTAGGCAGCTTGGA-3′ and 5′-ACCATAAGGCAGAACAGAAACCA-3′; c.308_309insAT, 5′-TAGGCCCTGGAACGTCTTTG-3′ and 5′- ACCATAAGGCAGAACAGAAACCA-3′. This mutation is likely to be pathogenic, because the *TTC8* gene has been reported as a causative gene for BBS8^[@CR4]^. The nonsense mutation was located in exon 3 of the *TTC8* gene, thus producing a truncated protein without tetratricopeptide repeats 11 and 15, which are involved in pilus formation and twitching mobility. The frameshift mutation in exon 5 (c.309_310insTA) generates a premature stop codon in exon 6, which also produces TTC8 lacking normal tetratricopeptide repeats 11 and 15. The premature stop codon is located before the last exon; notably, a mRNA transcribed from a gene with a truncating mutation often undergoes nonsense-mediated mRNA decay before translation^[@CR5]^. Thus, transcripts with nonsense and frameshift mutations are likely to be rapidly degraded to reduce the translation of the truncated TTC8 protein. Therefore, this compound heterozygous patient would not have a functional TTC8 protein to support the formation of the BBSome, leading to the development of BBS. His mother exhibited the heterozygous nonsense mutation, but no frameshift mutation. Although the genetic and clinical data were not available from his father, this patient's BBS was determined to result from a compound heterozygous *TTC8* gene mutation.

BBS patients with mutations in the *TTC8* gene comprise only 2.8% of all BSS patients^[@CR6],[@CR7]^. In Japan, the genetics of four BBS families have been reported: *BBS2*, *BBS5*, and *BBS7* homozygotes, as well as a *BBS10* compound heterozygote^[@CR8],[@CR9]^. To the best of our knowledge, this is the first BBS patient with a mutation in the *TTC8* gene in Japan. Thus far, 16 families with the *TTC8* genetic abnormality have been reported (Table [2](#Tab2){ref-type="table"})^[@CR4],[@CR7],[@CR10]--[@CR15]^. Most of these families have homozygous mutations; only our patient and a Hispanic family were compound heterozygotes. Although full clinical information was not available for some cases, most of the cases in these 16 families exhibit classical BBS without obvious differences in phenotypes.Table 2List of variants and phenotype reported in patients of BBS8FamilyEthnicConsanguineousGeneNucleotide alteration(s)Zygosity stateAlteration(s) in coding sequenceRod-cone dystrophyPolydactylyObesityHypogonadismRenal anomaliesMental retardationSecondary signsReferenceFamily 1JapaneseNo*TTC8*226 C \> T & 308_309insATcomp. hetQ76X & T103fsYesYesYesNoYesNoHirschsprung disease, abnormal glucose tolerance, exotropia, hypertensionPresent studyFamily 2PakistanYes*TTC8*IVS10 + 2_4delTGChomSplice siteYesYesYesYesNASpeech impedimentDevelopmental delay, brachycephalyAnsley et al.^[@CR4]^Family 2PakistanYes*TTC8*IVS10 + 2_4delTGChomSplice siteYesYesYesYesNASpeech impedimentDevelopmental delay, brachycephaly, Situs inversusAnsley, et al.^[@CR4]^Family 2PakistanYes*TTC8*IVS10 + 2_4delTGChomSplice siteYesYesYesYesNASpeech impedimentDevelopmental delay, brachycephaly, hemophiliaAnsley, et al.^[@CR4]^Family 3Saudi ArabianNA*TTC8*187--188delEYhom6 bp Inframe delationYesYesYesYesNASpeech impedimentDevelopmental delay, brachycephalyAnsley, et al.^[@CR4]^Family 3Saudi ArabianNA*TTC8*187--188delEYhom6 bp Inframe delationYesYesYesYesNASpeech impedimentDevelopmental delay, brachycephalyAnsley, et al.^[@CR4]^Family 3Saudi ArabianNA*TTC8*187--188delEYhom6 bp Inframe delationYesYesYesNANASpeech impedimentDevelopmental delay, brachycephaly,deafnessAnsley, et al.^[@CR4]^Family 4Saudi ArabianNA*TTC8*187--188delEYhom6 bp Inframe delationYesYesYesNANASpeech impedimentDevelopmental delay, brachycephaly,hyposadiasAnsley, et al.^[@CR4]^Family 4Saudi ArabianNA*TTC8*187--188delEYhom6 bp Inframe delationYesYesYesNANASpeech impedimentDevelopmental delay, brachycephaly,asthmaAnsley, et al.^[@CR4]^Family 5North AfricanYes*TTC8*459 G \> AhomSplice siteYesYesNANANACognitive impairmentMicropenisStoetzel, et al.^[@CR7]^Family 5North AfricanYes*TTC8*459 G \> AhomSplice siteYesYesNANAYesNAHydrometrocolposStoetzel, et al.^[@CR7]^Family 5North AfricanYes*TTC8*459 G \> AhomSplice siteYesYesNANAYesNANAStoetzel, et al.^[@CR7]^Family 6LebaneseYes*TTC8*IVS6 + 1_G \> AhomSplice siteNANANANANANANAStoetzel, et al.^[@CR7]^Family 7CaucasianNo*TTC8*IVS6 + 1--2delGThetSplice siteNANANANANANANAStoetzel, et al.^[@CR7]^Family 8TunisianNA*TTC8*459 + 1 G \> AhomPro101LeufsX12NANANANANANANASmaoui, et al.^[@CR10]^Family 9TunisianNA*TTC8*459 + 1 G \> AhomPro101LeufsX12NANANANANANANASmaoui, et al.^[@CR10]^Family10\*TunisianNA*TTC8*355_356insGGTGGAAGGCCAGGCAhomThr124ArgfsX43NANANANANANANASmaoui, et al.^[@CR10]^Family 11TurkeyYes*TTC8*122 G \> AhomW41XYesYesYesYesNoNAYes but details unknownHarville, et al.^[@CR11]^Family 12NANA*TTC8*IVS2 + 1 G \> AhomSplice siteYesYesYes?NoNoYesAsthma, nasal cephaloceleJanssen, et al.^[@CR12]^Family 13HispanicNA*TTC8*485delG & 1000delAcomp. hetG162fsX4 & I334fsX1YesYesYesYesYesYesFatty liver, gall stonesJanssen, et al.^[@CR12]^Family 14TunisianYes*TTC8*329 G \> AhomSplice siteNANANANANANANARedin, et al.^[@CR13]^Family 15TunisianYes*TTC8*459 + 1 G \> AhomSplice siteYesYesYesYesYesNADental anomalies, hypertensionM'hamdi O, et al.^[@CR14]^Family 16PakistanYes*TTC8*1347 G \> ChomGln449HisYesYesYesYesNoCongnitive impairmentClinodactylyUllah, et al.^[@CR15]^Family 16PakistanYes*TTC8*1347 G \> ChomGln449HisYesYesYesYesNACongnitive impairmentClinodactylyUllah, et al.^[@CR15]^Family 16PakistanYes*TTC8*1347 G \> ChomGln449HisYesYesYesNANoCongnitive impairmentNAUllah, et al.^[@CR15]^

In summary, we identified a novel compound heterozygous mutation in a Japanese BBS patient by WES. Our findings suggest that WES may be a useful tool for genetic diagnosis and characterization of BBS.
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